Pfizer: If vaccine-escape variant emerges, expects to develop, produce new vaccine in about 100 days
According to vaccine-maker Pfizer, in case there was a "vaccine-escape" variant, the company expects to be able to develop and produce a new tailor-made vaccine against that variant within about 100 days.
Market Reaction
The comments from Pfizer have offered little solace to a still overall very risk-off market. 100 days for a vaccine is good, but then nations would have to roll the vaccine out, which as seen in 2021, takes many months.
A vaccine-resistant variant, if that is what the new South African variant turns out to be, could still deliver a significant blow to the global economic outlook over the next six months if nations significantly tighten lockdowns and travel restrictions and consumers begin to fear the virus again.
Author
Joel Frank
Independent Analyst
Joel Frank is an economics graduate from the University of Birmingham and has worked as a full-time financial market analyst since 2018, specialising in the coverage of how developments in the global economy impact financial asset
